Precision medicine and testing for tumor biomarkers-are all tests born equal?

JAMA Oncology

Volumn 4, Issue 6, 2018, Pages 773-774

  Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; TUMOR MARKER; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ANALYTIC METHOD; BLOOD ANALYSIS; BRAF GENE; CANCER SCREENING; DEVICE APPROVAL; DIAGNOSTIC VALUE; DRUG USE; EGFR GENE; GENETIC DISORDER; GENETIC SCREENING; GOOD LABORATORY PRACTICE; HIGH THROUGHPUT SCREENING; HUMAN; LABORATORY TEST; LIQUID BIOPSY; MUTATIONAL ANALYSIS; NOTE; ONCOGENE K RAS; PATIENT CARE; PERSONALIZED MEDICINE; TISSUE PREPARATION;

BIOMARKERS, TUMOR; ERBB RECEPTORS; HUMANS; PRECISION MEDICINE; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85049756854     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2017.4018     Document Type: Note

References (12)

1. Teutsch SM, Bradley LA, Palomaki GE, et al; EGAPPWorking Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPPWorking Group. Genet Med. 2009;11(1):3-14.
2. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009;101 (21):1446-1452.
3. Evans BJ, BurkeW, Jarvik GP. The FDA and genomic tests-getting regulation right. N Engl JMed. 2015;372(23):2258-2264.
4. Sharfstein J. FDA regulation of laboratory-developed diagnostic tests. JAMA. 2015; 313(7):667-668.
5. Kim AS, Bartley AN, Bridge JA, et al. Comparison of laboratory-developed tests and FDA-approved assays for BRAF, EGFR, and KRAS testing [published online December 14, 2017]. JAMA Oncol. doi:10 .1001/jamaoncol.2017.4021
6. Leighl NB, Rekhtman N, BiermannWA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors. J Clin Oncol. 2014;32(32):3673-3679.
7. Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer. J Clin Oncol. 2017;35(13):1453-1486.
8. Wolff AC, Hammond ME, Hicks DG, et al; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2013;31(31):3997-4013.
9. Hammond ME, Hayes DF,Wolff AC. Clinical notice for American Society of Clinical Oncology?College of American Pathologists guideline recommendations on ER/PgR and HER2 testing in breast cancer. J Clin Oncol. 2011;29(15): e458.
10. Torga G, Pienta KJ. Patient-paired sample congruence between 2 commercial liquid biopsy tests[published online December 14, 2017]. JAMA Oncol. doi:10.1001/jamaoncol.2017.4027
11. Tannock IF, Hickman JA. Limits to precision cancer medicine. N Engl J Med. 2017;376(1):96-97.
12. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8): 1014-1022.